Bruchard Mélanie, Ghiringhelli François
INSERM U866, Facultés de médecine et de pharmacie, Centre de recherche, 7 Bd Jeanne-d'Arc, 21079 Dijon, France.
INSERM U866, Facultés de médecine et de pharmacie, Centre de recherche, 7 Bd Jeanne-d'Arc, 21079 Dijon, France, Centre Georges-Francois-Leclerc, 21079 Dijon, France.
Bull Cancer. 2014 Jun;101(6):605-7. doi: 10.1684/bdc.2014.1936.
MDSC (myeloid derived suppressor cells) are immature cells from myeloid origin that accumulate in spleen and tumor bed during tumor growth and that can suppress anti-tumor immunity by various ways. Two chemotherapeutic agents, 5-fluorouracil and gemcitabin, that are commonly used in the treatment of colon cancer and pancreatic cancer, can selectively kill MDSC. Beneficial effects of 5-Fluorouracil and gemcitabin are however temporary. After treatment with those chemotherapies, an activation of the NLRP3 inflammasome is observed in MDSC, due to an interaction between cathepsin B and NLRP3, which leads to the production of IL-1β thus increasing pro-tumor immune responses. IL-1β enhances the production of IL-17 by CD4 T cells which in turn favors angiogenesis and tumor growth.
髓源性抑制细胞(MDSC)是起源于髓系的未成熟细胞,在肿瘤生长过程中积聚于脾脏和肿瘤床,可通过多种方式抑制抗肿瘤免疫。两种常用于治疗结肠癌和胰腺癌的化疗药物5-氟尿嘧啶和吉西他滨,可选择性杀死MDSC。然而,5-氟尿嘧啶和吉西他滨的有益作用是暂时的。用这些化疗药物治疗后,由于组织蛋白酶B与NLRP3之间的相互作用,在MDSC中观察到NLRP3炎性小体的激活,这导致IL-1β的产生,从而增加促肿瘤免疫反应。IL-1β增强CD4 T细胞产生IL-17,进而促进血管生成和肿瘤生长。